{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T10:44:28Z","timestamp":1771065868307,"version":"3.50.1"},"reference-count":17,"publisher":"American Veterinary Medical Association (AVMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["ajvr"],"published-print":{"date-parts":[[2013,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n<jats:p><jats:bold>Objective<\/jats:bold>\u2014To determine whether pimobendan has in vitro antithrombotic properties through inhibition of platelets in canine blood samples.<\/jats:p>\n<jats:p><jats:bold>Animals<\/jats:bold>\u201410 healthy adult dogs.<\/jats:p>\n<jats:p><jats:bold>Procedures<\/jats:bold>\u2014Blood samples were collected from each dog into tubes containing hirudin or sodium citrate. Pimobendan was added to blood samples (final concentration, 0.0, 0.01, 0.1, 1.0, or 10.0\u03bcM) containing hirudin prior to undergoing collagen- and ADP-induced whole blood impedance aggregometry. Plasma thromboxane concentrations were measured after platelet aggregation. Pimobendan was also added to blood samples (0.0, 0.01, or 10.0\u03bcM) containing sodium citrate prior to thromboelastographic evaluation.<\/jats:p>\n<jats:p><jats:bold>Results<\/jats:bold>\u2014Compared with findings for 0.0\u03bcM pimobendan, composite platelet aggregation (area under the curve [AUC]) and maximal platelet aggregation (aggregation units [AUs]) at 10.0\u03bcM pimobendan were significantly decreased for collagen-induced aggregation (AUC, 349.7 \u00b1 58.4 vs 285.1 \u00b1 72.2; maximal platelet aggregation, 196.2 \u00b1 25.8 AUs vs 161.5 \u00b1 38.0 AUs), and the AUC and velocity of aggregation at 10.0\u03bcM pimobendan were significantly decreased for ADP-induced aggregation (AUC, 268.5 \u00b1 35.1 vs 213.4 \u00b1 77.2; velocity of aggregation, 15.7 \u00b1 2.9 AUs\/min vs 11.8 \u00b1 3.5 AUs\/min). Pimobendan had no significant effect on plasma thromboxane concentration or thromboelastographic variables, regardless of concentration.<\/jats:p>\n<jats:p><jats:bold>Conclusions and Clinical Relevance<\/jats:bold>\u2014In vitro, pimobendan had an antiplatelet effect in canine blood samples at a concentration 1,000-fold higher than that clinically achievable. These antiplatelet properties do not appear to contribute to the positive clinical profile of the drug in dogs. Pimobendan administration would not appear to confer a risk for bleeding and does not have to be avoided in dogs with thrombocytopenia or those concurrently receiving antiplatelet drugs.<\/jats:p>","DOI":"10.2460\/ajvr.74.3.403","type":"journal-article","created":{"date-parts":[[2013,2,25]],"date-time":"2013-02-25T15:03:35Z","timestamp":1361804615000},"page":"403-407","source":"Crossref","is-referenced-by-count":11,"title":["In vitro effect of pimobendan on platelet aggregation in dogs"],"prefix":"10.2460","volume":"74","author":[{"given":"Eryn A.","family":"Shipley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel F.","family":"Hogan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nonya N.","family":"Fiakpui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aliya N.","family":"Magee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry W. Green","family":"III","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly A.","family":"Sederquist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1272","reference":[{"key":"ref1","series-title":"Vet Clin North Am Small Anim Pract","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/j.cvsm.2004.05.018","article-title":"Use of pimobendan in the management of heart failure","volume":"34","author":"Fuentes","year":"2004"},{"key":"ref2","series-title":"J Vet Intern Med","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1111\/j.1939-1676.2008.0150.x","article-title":"Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study","volume":"22","author":"Haggstrom","year":"2008"},{"key":"ref3","series-title":"J Vet Intern Med","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1111\/j.1939-1676.2009.0392.x","article-title":"Guidelines for the diagnosis and treatment of canine chronic valvular heart disease","volume":"23","author":"Atkins","year":"2009"},{"key":"ref4","series-title":"Vet Clin North Am Small Anim Pract","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.cvsm.2010.04.003","article-title":"Current use of pimobendan in canine patients with heart disease","volume":"40","author":"Boswood","year":"2010"},{"key":"ref5","series-title":"Biochem Pharmacol","first-page":"1153","article-title":"Taming platelets with cyclic nucleotides","volume":"62","author":"Schwarz","year":"2001"},{"key":"ref6","series-title":"Am J Vet Res","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.2460\/ajvr.68.12.1354","article-title":"Phosphodiesterase isoenzymes in equine platelets and their influence on platelet adhesion","volume":"68","author":"Dunkel","year":"2007"},{"key":"ref7","series-title":"Bioorg Med Chem Lett","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1016\/S0960-894X(02)00246-9","article-title":"Pyridazines. Part 28: 5-alkylidene-6-pheyl-3(2H)-pyridazinones, a new family of platelet aggregation inhibitors","volume":"12","author":"Sotelo","year":"2002"},{"key":"ref8","series-title":"Thromb Haemost","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1055\/s-0038-1661678","article-title":"Different aspects of aspirin, dipyridamole and UD-CG 115 on platelet activation in a model of vascular injury: studies with extracellular matrix covered with endothelial cells","volume":"56","author":"Eldor","year":"1986"},{"key":"ref9","series-title":"Cardiovasc Res","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1093\/cvr\/23.3.184","article-title":"Platelet aggregation inhibitory effects of the new positive inotropic agents pimobendan and UD-CG 212 in whole blood","volume":"23","author":"Saniabadi","year":"1989"},{"key":"ref10","series-title":"J Vet Cardiol","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jvc.2009.04.003","article-title":"Analysis of weight uniformity, content uniformity and 30-day stability in halves and quarters of routinely prescribed cardiovascular medications","volume":"11","author":"Margiocco","year":"2009"},{"key":"ref11","series-title":"Vetmedin [package insert]","year":"2007"},{"issue":"suppl 1","key":"ref12","series-title":"Br J Pharmacol","doi-asserted-by":"publisher","first-page":"S252","DOI":"10.1038\/sj.bjp.0706495","article-title":"Phosphodiesterase inhibitors","volume":"147","author":"Boswell-Smith","year":"2006"},{"key":"ref13","series-title":"Pharmacol Ther","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.pharmthera.2005.07.003","article-title":"Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents","volume":"109","author":"Lugnier","year":"2006"},{"key":"ref14","series-title":"Heart Fail Rev","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s10741-008-9130-x","article-title":"Phosphodiesterase inhibition in heart failure","volume":"14","author":"Movsesian","year":"2009"},{"key":"ref15","series-title":"Thromb Res","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/0049-3848(93)90097-8","article-title":"Effect of milrinone in human platelet shape change, aggregation, and thromboxane A2 synthesis: an in vitro study","volume":"71","author":"Barradas","year":"1993"},{"key":"ref16","series-title":"Gen Pharmacol","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/S0306-3623(96)00050-X","article-title":"Interplay between milrinone and adenosine in the inhibition of human platelet response","volume":"27","author":"Anfossi","year":"1996"},{"key":"ref17","series-title":"Thromb Haemost","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1055\/s-0037-1613099","article-title":"Differential regulation of human platelet responses by cGMP inhibited and stimulated cAMP phosphodiesterases","volume":"87","author":"Manns","year":"2002"}],"container-title":["American Journal of Veterinary Research"],"original-title":[],"link":[{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/ajvr\/74\/3\/ajvr.74.3.403.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/avmajournals.avma.org\/downloadpdf\/journals\/ajvr\/74\/3\/ajvr.74.3.403.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/avmajournals.avma.org\/downloadpdf\/journals\/ajvr\/74\/3\/ajvr.74.3.403.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T12:33:21Z","timestamp":1741350801000},"score":1,"resource":{"primary":{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/ajvr\/74\/3\/ajvr.74.3.403.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":17,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.2460\/ajvr.74.3.403","relation":{},"ISSN":["0002-9645"],"issn-type":[{"value":"0002-9645","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3]]}}}